JinkoSolar, a leading solar module manufacturer, filed a patent infringement lawsuit against VSUN Solar USA and Toyo Co., alleging misuse of its proprietary N-type TOPCon technology. The lawsuit sent JKS stock prices surging, highlighting the company’s commitment to protecting its extensive intellectual property portfolio.
Nintendo and The Pokémon Company have filed a lawsuit against Pocketpair, the developer of Palworld, alleging patent infringement in Japan. The lawsuit, which seeks financial damages and a ban on the game’s release in Japan, focuses on core gameplay mechanics similar to those found in Pokémon games. Pocketpair has vowed to defend its position in court, but the legal battle could significantly impact the availability of Palworld.
A Delaware jury has ruled in favor of Apple in a patent infringement case against Masimo, awarding Apple a symbolic $250 in damages. The jury found that Masimo infringed on Apple’s patents related to health technology in older smartwatch models, but current Masimo products were not found to infringe. This legal battle, which began in 2022, has been a point of contention between the two companies and highlights the competitive landscape in the wearables market.
Pharmaceutical giant GSK has filed a lawsuit against Moderna, claiming that Moderna’s mRNA vaccines infringe on patents developed by GSK. GSK asserts that its groundbreaking mRNA vaccine platform, pioneered over a decade ago, is the foundation for Moderna’s successful vaccines. This lawsuit highlights a major battle over intellectual property rights in the rapidly developing field of mRNA vaccines, with implications for future vaccine development and the global fight against infectious diseases.
Nintendo has filed a lawsuit against Palworld developer Pocketpair, alleging patent infringement related to a Pokeball-like capture system. The patent, which details animations and mechanics for capturing in-game creatures with a throwable sphere, appears to be the crux of the lawsuit. While Pocketpair has denied knowledge of specific patent violations, Nintendo seems confident in its legal standing.
Alnylam Pharmaceuticals has dropped its patent infringement lawsuit against Moderna, conceding that Moderna’s COVID-19 vaccine formulation does not infringe on its patents. The case centered around Alnylam’s patent on lipid nanoparticle (LNP) technology used for delivering genetic material into cells. The settlement allows for the entry of judgment in favor of Moderna, effectively ending the legal dispute.
Nintendo and The Pokémon Company are taking legal action against indie game developer Pocketpair for alleged patent infringement in their monster-catching game, Palworld. The lawsuit focuses on a patent for the game’s core capture mechanic, which is very similar to Pokémon’s. This could have significant ramifications for Palworld’s future, potentially impacting its availability on various platforms.
Nintendo and The Pokémon Company have filed a lawsuit against Pocketpair, the developer of the popular creature-collecting survival game Palworld, for patent infringement. The lawsuit, filed in Japan, alleges that Palworld infringes upon multiple patent rights related to Pokémon gameplay mechanics. While the specific patents in question remain undisclosed, speculation is rife about Nintendo’s potential claims.
Paltalk, Inc. (PALT) received a $65.7 million verdict against Cisco Systems, Inc. (CSCO) in a patent infringement lawsuit. Despite the substantial award, Paltalk’s shares are trading lower due to potential post-trial proceedings and significant litigation costs. The company recently reported a decline in revenue and a net loss for the second quarter.
Novartis AG, the pharmaceutical giant, has suffered a legal setback in its efforts to prevent the launch of a generic version of its blockbuster heart-failure drug, Entresto. A federal court ruled against Novartis’ request to block MSN Pharmaceuticals from launching its generic version, citing a low likelihood of winning the patent infringement lawsuit. While the ruling temporarily suspends MSN’s sales pending an appeal, it marks a significant blow to Novartis’ efforts to protect its intellectual property and maintain market dominance for Entresto, its top-selling drug.
